Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-05

FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)

View source ↗

Summary

Ardelyx submitted a supplemental application to the FDA for IBSRELA (tenapanor hydrochloride) related to its labeling for irritable bowel syndrome with constipa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBSRELA (tenapanor hydrochloride)

Snippet

SUPPL AP for IBSRELA (TENAPANOR HYDROCHLORIDE)